The clinical effectiveness agency for England and Wales said March 23 that it would formally recommend azacitidine as a first-line treatment for intermediate and high-risk myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. Azacitidine had been rejected by the National Institute for Health and Clinical Excellence last spring over cost concerns. That decision was met with fierce opposition by the Royal College of Physicians, the Royal College of Pathologists, the...